IE
AVTX icon

Israel Englander’s Avalo Therapeutics AVTX Stock Holding History

Israel Englander’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-835,484
Closed -$12.5M – 5848
2026
Q1 		$12.5M Buy
835,484
+175,505
+27% +$2.74M 0.01% 1960
2025
Q4 		$12M Buy
659,979
+522,548
+380% +$8.82M 0.01% 2073
2025
Q3 		$1.75M Buy
+137,431
New +$1.18M ﹤0.01% 4186
2023
Q3 		– Sell
-141
Closed -$12.1K – 6107
2023
Q2 		$12.1K Sell
141
-119
-46% -$80.1K ﹤0.01% 5732
2023
Q1 		$109K Buy
260
+80
+44% +$63K ﹤0.01% 5394
2022
Q4 		$220K Sell
180
-33
-15% -$43K ﹤0.01% 5279
2022
Q3 		$169K Sell
213
-138
-39% -$150K ﹤0.01% 5751
2022
Q2 		$506K Buy
+351
New +$470K ﹤0.01% 4942
2021
Q4 		– Sell
-65
Closed -$411K – 6772
2021
Q3 		$411K Sell
65
-1
-2% -$8.11K ﹤0.01% 5521
2021
Q2 		$621K Buy
66
+61
+1,220% +$511K ﹤0.01% 5108
2021
Q1 		$43K Buy
+5
New +$47.2K ﹤0.01% 5784
2020
Q4 		– Sell
-6
Closed -$39 – 5185
2020
Q3 		$39 Sell
6
-49
-89% -$368K ﹤0.01% 4314
2020
Q2 		$413K Buy
55
+31
+129% +$225K ﹤0.01% 3517
2020
Q1 		$168K Buy
+24
New +$254K ﹤0.01% 3441
2019
Q4 		– Sell
-32
Closed -$305K – 4193
2019
Q3 		$305K Buy
+32
New +$357K ﹤0.01% 3557
2019
Q2 		– Sell
-51
Closed -$861K – 4040
2019
Q1 		$861K Buy
51
+46
+920% +$688K ﹤0.01% 2953
2018
Q4 		$44K Sell
5
-17
-77% -$189K ﹤0.01% 3624
2018
Q3 		$292K Buy
+22
New +$288K ﹤0.01% 3494
2016
Q3 		– Sell
-5
Closed -$29K – 3259
2016
Q2 		$29K Sell
5
-9
-64% -$81.8K ﹤0.01% 3093
2016
Q1 		$150K Buy
+14
New +$138K ﹤0.01% 3016

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Israel Englander's AVTX Position: Q2 2026 in Review

Israel Englander sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 835,484 shares — an estimated $12.5M sold.

Israel Englander first reported a position in AVTX in Q1 2016 and held it in 20 quarters. The position peaked at $12.5M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Israel Englander reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 835,484 Avalo Therapeutics shares in Q2 2026, an estimated $12.5M.
  • Israel Englander first reported a position in Avalo Therapeutics in Q1 2016 and held it in 20 quarters.
  • Israel Englander's Avalo Therapeutics position peaked at $12.5M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.